Cipla has classified its current Good Manufacturing Practices (cGMP) inspection of the company`s manufacturing facility in Virgonagar, Bengaluru, conducted between 7 � 13 November 2024, as Voluntary Action Indicated (VAI). Powered by Capital Market - Live News

Cipla will invest approx. ZAR 900 million in equity share capital of Cipla Medpro South Africa Proprietary Limited, a wholly-owned subsidiary of the Company in South Africa (CMSA). CMSA, is a wholly owned subsidiary of Cipla, and is the holding company for the group operations in South Africa. The group is involved in the manufacturing, marketing, and supply of pharmaceutical products. The investment will be utilised to reduce inter-group debt and improve the capital structure of CMSA and its subsidiaries. Powered by Capital Market - Live News

Net profit of Cipla rose 48.74% to Rs 1570.51 crore in the quarter ended December 2024 as against Rs 1055.90 crore during the previous quarter ended December 2023. Sales rose 7.01% to Rs 6961.60 crore in the quarter ended December 2024 as against Rs 6505.66 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales6961.606505.66 7 OPM %28.5726.86 - PBDT2195.891902.06 15 PBT1916.091668.63 15 NP1570.511055.90 49 Powered by Capital Market - Live News

Cipla will hold a meeting of the Board of Directors of the Company on 28 January 2025.Powered by Capital Market - Live News

Cipla has allotted 17,064 fully paid-up equity shares of Rs 2 each, pursuant to exercise of employee stock options / stock appreciation rights under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company.Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to Rs 1,61,52,25,016 comprising of 80,76,12,508 equity shares of face value Rs 2 each. Powered by Capital Market - Live News